Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Revive Therapeutics Ltd.

< Previous 1 2 Next >
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:PHRM CSE:RVV PHRRF RVVTF
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:MDMA CSE:PHRM CSE:RVV PHRRF RVVTF
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Ltd. Closes $4.3 Million Offering
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Ltd. Expands Life Offering to Quebec
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via GlobeNewswire
Tickers CSE:RVV RVVTF
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.